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Effects of L- and D-arginine and some related esters on the
cytosolic mechanisms of a-thrombin-induced human platelet
activation
'Paola Failli, Enrica Cecchi, C. Ruocco, A. Fazzini & A. Giotti
Dipartimento di Farmacologia Preclinica e Clinica 'M. Aiazzi Mancini' and Centro Interuniversitario 'Ipossie', V. le G.B.
Morgagni, 65, University of Florence, 50134 Florence, Italy
1 In Fura-2 preloaded human platelets, the increase in cytosolic calcium induced by a-thrombin was
reduced by some L- and D-arginine ester compounds the IC50 (#uM) values of which were 7.4 for TAEE,
56.9 for BAEE, 77.6 for TAME, 560 for T(d)AME, 656.3 for L-ArgOMe and 2206.7 for D-ArgOMe.
x-tosyl-L-Arginine, L- and D-arginine were inactive.
2 The inhibitory activity of the L-arginine esters was not modified when platelets were pretreated with
100 LM Nw-monomethyl-L-arginine.
3 The L-arginine esters did not increase cyclic GMP content in platelets either in the presence or
absence of indomethacin and apyrase at rest and after a-thrombin stimulation.
4 The kinetic parameters of platelet Na+/H+ antiporter (amiloride-inhibitable, evaluated after cytosolic
nigericin-induced acidification) were modified by L- and D-arginine esters, while the native amino acids
were ineffective.
5 The inhibitory effects of the L- and D-arginine esters on platelet activation appear to be mainly due
to their inhibitory effect on Na+/H+ antiporter.
Keywords: Human platelets; a-thrombin activation; cytosolic calcium concentration; Na+/H+ antiporter activity; L-arginine;
D-arginine; L-arginine esters; D-arginine esters; N0-monomethyl-L-arginine
Introduction
Recent data from many laboratories point to the role of
L-arginine in a wide range of physiological functions (Mon-
cada et al., 1991), including platelet aggregation (Radomski
et al., 1987; 1990a,b). L-Arginine has been found to be
directly linked to the production of endothelial-derived
relaxing factor (EDRF), which has been identified as nitric
oxide (Palmer et al., 1987; Ignarro et al., 1987), one of the
two nitrogen atoms of the guanidine group of the amino acid
being oxidized to produce nitric oxide. The biochemical
pathway for synthesizing nitric oxide from L-arginine is com-
petitively inhibited by guanidine-substituted L-arginine deriv-
atives such as Nw-monomethyl-L-arginine (L-NMMA) (Hibbs
et al., 1987; Moncada et al., 1991). Nitric oxide appears to
exert its action through activation of a soluble guanylate
cyclase and hence an increase in guanosine 3': 5'-cyclic
monophosphate (cyclic GMP) formation.
It has been proposed not only that L-arginine might be the
substrate for the production of nitric oxide, but also that
some L-arginine derivatives may induce endothelium-depen-
dent relaxation in different vascular beds by increasing nitric
oxide synthesis (Thomas & Ramwell, 1988; Al-Swayeh &
Moore, 1989; Thomas et al., 1990; Busija et al., 1990; Farhat
et al., 1990a,b). More recently it has been reported that the
vasorelaxation induced by N-a-benzoyl-L-arginine ethyl ester
(BAEE) is either not nitric oxide-dependent (Al-Swayeh &
Moore, 1989; Fasehun et al., 1990; Schmidt et al., 1990) or is
only partially so (Farhat et al., 1990b), while N-a-tosyl-L-
arginine methyl ester (TAME) has been described as a nitric-
oxide-independent vasorelaxant (Schmidt et al., 1990) or an
endothelium-independent inhibitor of contraction induced by
several agents in human umbilical arteries (White, 1988).
Some of the L-arginine esters also inhibit platelet aggrega-
tion (Salzman & Chambers, 1964; Aoki et al., 1978; Failli et
al., 1990; Spurej et al., 1990). Preliminary data obtained in
our laboratory show that L- and D-arginine esters inhibit
aggregation induced by a-thrombin, while concentrations up
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to 500 t4M are ineffective against collagen-induced aggrega-
tion. In order to investigate the antiaggregatory mechanism
of arginine esters in human platelets stimulated by a-
thrombin, we have studied their effects against the increases
in cytosolic free calcium induced by a-thrombin: the experi-
mental conditions were chosen to rule out the amplification
mechanisms due to either arachidonic acid metabolites (in
particular thromboxane A2), or ADP by inhibiting arach-
idonic acid cyclo-oxygenase with indomethacin and by hyd-
rolyzing extraplatelet ADP with apyrase. The possible role of
L-arginine esters as nitric oxide precursors has also been
investigated, by measuring cyclic GMP platelet content. This
set of experiments was performed either in the presence of
indomethacin and apyrase or in their absence. Finally, we
have monitored Na+/H+ antiporter activity and its mod-
ification by the L- and D-arginine esters.
Some of these results were presented at the XIth Interna-
tional Congress of Pharmacology (Failli et al., 1990).
Methods
Platelet preparation
Blood was collected by venipuncture from healthy human
volunteers and immediately diluted 1/5 with citric acid:
trisodium citrate:glucose (1.5%:2.5%:2% w/v). Platelet-rich
plasma (PRP) was prepared by centrifugation at 500 g at
25°C for 15 min and incubated with 3 tLM Fura-2-AM or
2 tAM BCECF-AM at 37°C for 45 min.
Platelets were then washed twice by centrifugation and
resuspended in HEPES buffer of the following composition
(mM): NaCl 140, HEPES 10, NaHCO3 12, KCI 2.9, MgCl2
0.9, NaH2PO4 0.5 and glucose 10. Apyrase (100 u 1') was
added to hydrolyze ATP to ADP and ADP to AMP (Molnar
& Lorand, 1961) and indomethacin (10 LM) was added to
inhibit arachidonic acid cyclo-oxygenase. In experiments to
explore the effect of the D- and L-arginine esters on Na+/H+
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antiporter activity, BCECF-loaded platelets were washed
twice and suspended in a modified (nominally Na+ and
K+-free) N-methylglucamine buffer of the following composi-
tion (mM): N-methylglucamine 138, HEPES 10, glucose 10,
MgCl2 0.1, HCI 140 (adjusted to pH 7.4 with choline car-
bonate) (HEPES-N-methyl-glucamine buffer). D- and L-
Arginine esters were dissolved in either HEPES-NaHCO3 or
HEPES-N-methylglucamine buffer; the pH of the solutions
was measured and, if necessary, carefully adjusted.
Internal cytosolic free calcium concentrations ([Ca2+],)
were estimated in HEPES buffer 1 mM CaC12 according to
the method of Pollock & Rink (1986), using a Shimadzu
RF-5000 spectrofluorimeter (equipped with a thermostated
cuvette holder and magnetic stirrer), wavelength settings
being 345 nm for excitation and 500 nm for emission.
a-Thrombin was added directly to the cuvette in the presence
or absence of the test compound.
The Na+/H+ antiporter activity was determined by the
spectrofluorimetric technique described by Grinstein et al.
(1989). Briefly, BCECF-loaded platelets suspended in nom-
inally Na+- and K+-free N-methylglucamine buffer were
acidified by addition of nigericin. A typical acid-loading
experiment is shown in Figure 1. The decrease in fluorescence
(ordinate scale, arbitrary units) indicates the decrease in
intracytosolic pH (pHi). When the fluorescence value had
stabilized, the administration of 30 mM NaCl brought about
a rapid cytosolic alkalinization, indicating restored Na+/H+
antiporter activity. At the end of each experiment, the pH of
the buffer was measured in order to verify that the pH of the
medium had remained constant. Intracytosolic pH was then
calculated after platelet lysis, and the kinetic parameters of
the first phase of alkalinization were calculated after measur-
ing specific fluorescence of the BCECF at various pH values
and expressed as ApHi x min '.
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Test molecules were preincubated with platelet suspensions
for 2 min prior to adding a-thrombin.
Cyclic GMP measurement
Measurements of cyclic GMP were performed by radioim-
munoassay, using kits supplied by Amersham International.
In brief, twice-washed platelets were suspended at a density
of 108I- I0 platelets per 100 ,ul in indomethacin/apyrase
HEPES/NaHCO3 buffer, 1 mM CaC12, containing isobutyl-
methylxanthine (30 liM). In some experiments, indomethacin
and apyrase were not added. Test molecules were prein-
cubated with platelets at 37°C for 20 min and then
0.03 u ml1 ' a-thrombin (final concentration) or the same
volume of buffer was added. Incubation was continued for
an additional 5 min and then the reaction stopped by addi-
tion of 50 iLl cold 20% HC104 and transfer of the samples
onto ice for 5 min. The reaction mixture was neutralized with
110JLl 1.08 M K3P04, tubes were centrifuged and 3 aliquots
of supernatant (100 jil) were used for cyclic GMP determina-
tion.
Reagents
Amiloride HCI, N-methyl-D-glucamine, digitonin, D-arginine
(D-Arg), N-a-p-tosyl-L-arginine (a-tosyl-L-arginine), N-a-p-
tosyl-L-arginine methyl ester HCI (TAME), isobutylmethyl-
xanthine (IBMX), N-c-benzoyl-L-arginine ethyl ester HCI
(BAEE) and N-monomethyl-L-arginine acetate salt (L-
NMMA) were obtained from Sigma; L-arginine (L-Arg) and
sodium nitroprusside (NP) from Merck; L-arginine methyl
ester.2HCI (L-ArgOMe) from Fluka; nigericine (sodium
salt), Fura-2 and BCECF were from Calbiochem; Fura-2-
AM, BCECF-AM from Molecular Probes; a-thrombin from
Boehringer-Mannheim. All other reagents were of analytical
grade. D-Arginine methyl ester 2HCI (D-ArgOMe), N-a-p-
tosyl-D-arginine methyl ester HCI (T(d)AME), N-c-benzoyl-
D-arginine methyl ester HCI (B(d)AME) and N-ca-p-tosyl-L-
arginine ethyl ester HCI (TAEE) were the kind gift of Drs
Buzzetti and Sala of Italfarmaco (Milano, Italy).
Statistical analysis
All values are expressed as mean ± s.e.mean of the number
of experiments indicated and were compared by Student's t
test for paired data, with P<0.05 considered as statistically
significant. IC% values were estimated from at least 4
separate dose-effect curves by computerized linear regression
analysis.
Results
c
Internal calcium
Time
180 s
Figure 1 Acid-loading and activation of Na+/H+ antiporter of
BCECF-loaded platelets suspended in nominally Na+ and K+-free
N-methylglucamine buffer. Nigericin, 2 tM, was added to begin acid
loading in the absence of Na+ (first arrow). Na+/H+ antiporter was
then activated by addition of 30 mm NaCl (second arrow) in the
absence (a) or in the presence (b) of 1 mm amiloride. The bottom
trace (c) was obtained when, instead of NaCl, 30 mm choline
chloride was added at the second arrow (osmotic control). Abscissa
scale: time. Ordinate scale: fluorescence (arbitrary units), excitation
505 nm, emission 530 nm.
The average value for basal [Ca2J]i, measured within the 5 h
duration of experiments, was 145 ± 4 nM (n = 33). Addition
of a-thrombin induced a rapid, sustained and dose-dependent
increase in [Ca2+]i (Figure 2). A concentration-response curve
for a-thrombin was performed for each separate sample of
platelets in order to choose a suitable agonist concentration
for studying potential antagonists at equivalent activation
levels, i.e. around the half-maximal response. The concentra-
tion selected was between 0.03 u ml-' and 0.01 u ml-I (final).
L- or D-Arginine esters, added 2 min before stimulation,
did not influence basal [Ca2+]i values, but reduced the [Ca2]i
response induced by a-thrombin in a concentration-depen-
dent way; IC50 values are shown in Table 1. Esterification of
the parent amino acids engendered an antithrombin activity
in the compounds, with L-arginine esters being more active
than D-arginine esters. Sodium nitroprusside also con-
centration-dependently inhibits the [Ca2+]i response induced
by ca-thrombin, dose-dependently (ICo= 497.4 tM - Table
N
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Figure 2 Increases in internal free calcium ([Ca2+]i) induced by
a-thrombin on Fura-2 loaded platelets. a-Thrombin (0.05 uml--
0.001 u ml-') was added at the arrow. Abscissa scale: time. Left
ordinate scale: fluorescence (arbitrary units), excitation 345 nm, emis-
sion 500 nm; right ordinate scale: [Ca2+]i calibration scale.
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Figure 3 Effect of N-a-p-tosyl-L-arginine ethyl ester (TAEE) in the
presence (*) or absence (0) of 10I0M N4-monomethyl-L-arginine
(L-NMMA). Each point is the mean (± s.e.mean) of at least 3
experiments.
Table 1 ICn values CuM) of L- and D-argnine compounds
and sodium nitroprusside (NP) on the a-thrombin-induced
increase of [Ca2+]i in human platelets
Compounds
L-Arg
D-Arg
L-ArgOMe
D-ArgOMe
TAME
T(d)AME
TAEE
BAEE
B(d)AME
a-tosyl-L-arginine
NP
IC50 (AM)
No effect
No effect
656.3 (608-712)
2206.7 (1834-2769)
77.6 (50-138)
560.0 (430-810)
7.4 (5-12)
56.9 (47-71)
No effect
No effect
497.4 (339-932)
Confidence limits in parentheses.
For abbreviations, see text.
1). Unesterified L-arginine was ineffective, even when prein-
cubated at a high concentration (10mM) with platelets for
30 min at 37°C. The increase in [Ca2"Ji induced by a-
thrombin was not modified by preincubating platelets
(30min at 37°C) with 100 M L-NMMA, the increase being
701 ± 51 nM and 692 ± 51 nM with and without L-NMMA
respectively (mean of at least 17 different detenninations).
Nw-monomethyl-L-arginine (100 pM) did not diminish the
inhibitory effect of L-arginine esters TAEE, BAEE, TAME
tested in the ratios 1: 1, 1: 10, 1:100. Figure 3 shows results
for the most effective compound, TAEE. Inhibition by one of
the least active esters, L-ArgOMe (1 mM) was also not
modified by L-NMMA (36.3 ± 12% inhibition in the absence
and 45.3 ± 10% inhibition in the presence of 100 tiM L-
NMMA; mean of 4 experiments).
Cyclic GMP content
Experiments in the presence of indomethacin and apyrase
Cyclic GMP content of human platelets was 0.67 +
0.14 pmol per 108 platelets in basal conditions and 0.73 +
0.1 pmol per 108 platelets after x-thrombin stimulation in
indomethacin/apyrase HEPES/NaHCO3 buffer, I mM CaCl2.
These values were increased in a dose-dependent manner by
1, 10 and 100gM sodium nitroprusside. At the maximal
concentration tested (100 gLM), sodium nitroprusside increased
the basal content of cyclic GMP to 1.5 ± 0.25 pmol per 108
platelets (P <0.05 vs no drugs at rest) and 1.9 ± 0.45 pmol
per 108 platelets (P<0.05 vs no drugs after a-thrombin
administration), respectively, at rest and after a-thrombin
stimulation (Figure 4a). Neither L-arginine esters (at concen-
trations near to their IC50 values for inhibition of a-
thrombin-induced [Ca2+]i increase) nor 100 LM L-arginine
increased platelet cyclic GMP content (Figure 4a).
Experiments in the absence of indomethacin and apyrase In
these experimental conditions, cyclic GMP content of human
platelets was 0.5 ± 0.13 pmol per 108 platelets in basal condi-
tions and 0.97 ± 0.18 pmol per 108 platelets after a-thrombin
stimulation. Sodium nitroprusside (100 ,sM) increased cyclic
GMP content in unstimulated platelets by about 18 fold
(P<0.001 vs no drugs at rest) and by about 9 fold after
a-thrombin stimulation (P <0.0001 vs no drugs after a-
thrombin stimulation, Figure 4b). However, L-arginine esters
did not increase this content either at rest or after a-thrombin
stimulation (Figure 4b). Preincubation with L-arginine
(100 j4M) did not increase cyclic GMP content in unstim-
ulated platelets (0.63 ± 0.13 and 0.5 ± 0.13 pmol per 108
platelets L-arginine and no drugs at rest respectively, P<0.5,
not significant), while a-thrombin (administered after 20 min
preincubation with 100 JM L-arginine) increased it (0.63 +
0.13 pmol per 108 platelets to 1.25 ± 0.14 pmol per 108
platelets, P<0.05 vs L-arginine at rest, Figure 4b). However,
platelet cyclic GMP content after L-arginine (100 fiM) and
a-thrombin did not differ from that in a-thrombin-treated
platelets, being 1.25 ± 0.14 pmol per 108 platelets and
0.97 ± 0.18 pmol per 108 platelets, respectively (P<0.295,
not significant).
Na+/H+ antiporter activity
After the administration of 30mM Na+ ions in acid-loaded
platelets, the pHi began to increase rapidly (1.20 ± 0.12 pH
units min ', Figure 1 and Table 2, control). Amiloride
(1 mM) strongly modified this response (Figure 1 and Table
2), while choline chloride did not induce any changes in pH,
(Figure 1 and Table 2). The effects of L- and D-arginine esters
on Na+/H+ antiporter activity are summarized in Table 2.
The most active compound was TAEE, its effect being
concentration-dependent in the range 0.5-0.01 mM. L-
Arginine and D-arginine, although tested at 20 mM, were
inactive (Table 2).
Discussion
Our data show that some methyl- and ethyl esters of both D-
and L-arginine inhibit the [Ca2+]J increase induced in Fura-2
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Table 2 Effects of amiloride, L- and D-arginine and L- and D-
arginine esters on Na+/H+ antiporter activity in human platelets
*~~~~~~~~L
~~I I I~~ji
A~ (~ * W liij~~~
;_pe <-O,05
a'':2 8 8 I. .8 °
w- m-
-U.L
z CL CD 0 ! Bc it.20. CD~~~~~~. A
I~oA2
Figure 4 (a) Effect of L-arginine esters (tested at concentrations near
their ICn values for inhibition of a-thrombin-induced [Ca2+]i in-
crease) in comparison with 100 jAM sodium nitroprusside (NP) and
100 f&M L-arginine on cyclic GMP concentration measured in human
platelets suspended in HEPES/NaHCO3 buffer containing 1 mM
CaCl2, 1O JM indomethacin, 100 u ml- apyrase and 30 jAM isobutyl
methyl xanthine (IBMX), estimated either at rest (solid columns) or
after stimulation by a-thrombin (0.03 u ml- ') (hatched columns).
Values are the mean ( ± s.e.mean) of at least 3 experiments.
*P< 0.05 vs no drugs. (b) Effect of L-arginine esters (tested at
concentrations near their IC50 values for inhibition of a-thrombin-
induced [Ca2+], increase) in comparison with 1OOJM sodium nitro-
prusside (NP) and 100 AM L-arginine on cyclic GMP concentration
measured in human platelets suspended in HEPES/NaHCO3 buffer
containing 1 mM CaCl2 and 30 JAM isobutyl methyl xanthine (IBMX),
estimated either at rest (solid columns) or after stimulation by a-
thrombin (0.03 u m1') (hatched columns). Values are the mean
(±s.e.mean) of at least 3 experiments. **P<O.OO1 vs no drugs;
***P<O.OOO1 vs no drugs.
loaded human platelets by a-thrombin. The inhibitory
activities of these esters are increased by substitutions on the
primary a-amino group, tosyl substitution being more
effective than benzoyl. It is also interesting to note that ethyl
esters are more effective than methyl esters (TAME <
TAEE).
In the same experimental conditions, sodium nitroprusside,
which increases cyclic GMP content through a direct act-
ivation of soluble NO-sensitive guanylate cyclase, reduced
No drugs
Control (30mM NaCI)
Choline chloride (30 mM)
Compounds
Amiloride (1 mM)
Amiloride (0.1 mM)
TAEE (0.5 mM)
TAEE (0.1 mM)
TAEE (0.01 mM)
BAEE (0.5 mM)
BAEE (0.1 mM)
TAME (1 mM)
TAME (0.1 mM)
L-ArgOMe (10 mM)
D-ArgOMe (10 mM)
iL-Arg (20 mM)
D-Arg (20 mM)
For abbreviations, see text.
Values are mean ± s.e.mean of at
experiments.
*P<0.05; **P<0.01; ***P<0.001.
ApHmin-'
1.20 ± 0.12
0.00
0.37 ± 0.08*
0.64 0.25
0.29 0.10**
0.41 ± 0.13**
0.51 + 0.08*
0.67 0.13*
0.71 ± 0.14
0.29± 0.10***
0.33 0.12*
0.29 0.06**
0.34 ± 0.15*
1.04 0.31
0.66 0.26
least 3 different
a-thrombin-induced [Ca2+]i increase in platelets in a dose-
dependent way, suggesting that an increase in platelet cyclic
GMP content (Figure 4a) reduces [Ca2+]i increase induced by
a-thrombin stimulation.
The suggestion that some L-arginine esters might influence
cellular function by increasing nitric oxide synthesis (see
Introduction) seems an unsatisfactory explanation of the
inhibitory effects observed in our experimental conditions. In
fact, a high concentration (100 JM) of the NO-synthase
inhibitor L-NMMA did not modify the inhibition induced by
the compounds. Moreover, L-arginine esters did not increase
platelet cyclic GMP content either in the presence of
indomethacin and apyrase or in their absence (Figure 4a and
b).
On the other hand, in the experimental conditions in which
we measured [Ca2J]i (i.e. in the presence of indomethacin and
apyrase), the NO-synthase pathway from L-arginine seems
not to be activated. L-Arginine did not in fact inhibit the
[Ca2+]i increase induced by a-thrombin, either with or with-
out a 30min preincubation time at 37°C. Moreover, 100 iM
L-NMMA did not modify a-thrombin-induced [Ca2+]i in-
crease. Furthermore, although 100 JAM L-arginine (prein-
cubated 20 min) and a-thrombin induced an increase in
platelet cyclic GMP content in the absence of indomethacin
and apyrase (Figure 4b), this increase seems to be too small
to reduce a-thrombin-induced [Ca2+], increase. In fact, a
small dose of sodium nitroprusside (1 pM), which induced a
similar increase in platelet cyclic GMP content (52%,
measured in the same experimental conditions as [Ca2]i
determination) hardly affected a-thrombin-induced [Ca2+]i
increase (< 10% inhibition). This result is compatible with
the weak inhibition by L-arginine of thrombin-induced agg-
regation of human platelets (Radomski et al., 1990a,b).
We have shown that some of the L- and D-arginine esters
inhibit Na+/H+ antiporter activity, as demonstrated by
analysing the early phase of Na+/H+ activation. Further-
more, the potencies for the inhibition of the Na+/H+
antiporter were correlated with potencies for inhibiting the
[Ca2+]i increase induced by a-thrombin, the most effective of
the esters being TAEE. More intriguing is the inhibitory
effect of T(d)AME on the [Ca2+], increase induced by
a-thrombin, as the Na+/H+ antiporter activity was not
affected by 1 mM or 0.1 mM T(d)AME (94% and 92% of the
control, respectively). Further research will be necessary in
order to clarify the effect of this compound.
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Although the role of Na+/H+ antiporter activation in the
induction of aggregation and [Ca2+]i increase in platelets is a
matter of debate (Siffert & Akkermann, 1987; Simpson &
Rink, 1987; Hunyady et al., 1987; Zavoico & Cragoe, 1988;
Ghigo et al., 1988; Sanchez et al., 1988; Siffert et al., 1989),
we suggest that the effect of L-arginine esters on the Na+/H+
antiporter activity may be the basis of their inhibitory action
on a-thrombin-induced [Ca2+]J increase and aggregation;
indeed the prototype inhibitor of the Na+/H+ antiporter,
amiloride, also inhibits platelet aggregation (Siffert et al.,
1986).
The L-arginine esters were also inhibitors of a-thrombin-
induced aggregation, IC50 values being 15.2 iLM, 18.0 tLM and
26.3 tLM for TAEE, TAME and BAEE, respectively (results
not shown). In contrast, concentrations up to 500 yiM of
TAEE, TAME and BAEE were completely ineffective as
inhibitors of collagen-induced aggregation, a mechanism of
platelet activation which is independent of the activation of the
Na+/H+ antiporter (Joseph et al., 1990). All these data sup-
port the hypothesis that the mechanism of action of L-arginine
esters is the inhibition of Na+/H+ antiporter activity.
Recently, the thrombin human platelet receptor has been
cloned and functionally characterized (Vu et al., 1991). It
seems that thrombin binding with its receptor sites is charac-
terized by a partial proteolytic digestion of an extraplatelet
domain. Although we cannot rule out the possibility that the
antithrombin effect of L-arginine esters is an antiproteolytic
process, preliminary results indicate that L-arginine esters
inhibit the proteolytic effect of a-thrombin only at concentra-
tions which are 10 times greater than those required to
inhibit the [Ca2+]i increase after a-thrombin (unpublished
observations). Therefore, this property is unlikely to explain
the inhibitory effect of the compounds. In fact, subthreshold
antiproteolytic concentrations are fully active in inhibiting
the [Ca2J]i increase induced by o-thrombin. Moreover, in
PRP, BAEE inhibits thrombin-induced platelet aggregation
without inhibiting fibrin clot formation (Spurej et al., 1990).
In conclusion, our observations are consistent with the
interpretation that pharmacological actions of some arginine
esters may be linked to their inhibitory effect on platelet
Na+/H+ antiporter activity. For instance, this property
might also explain some of the endothelium-independent (or
only partially endothelium-dependent) effects of L-arginine
esters described by other authors (White, 1988; Schmidt et
al., 1990; Farhat et al., 1990; Fasehun et al., 1990).
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